BIA Ceuticals

Company Overview

Snapshot

Founded in February 2017 by Guy Landver, Tom Gross, and Eytan Moor, BIA Ceuticals operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing natural remedies.

Business overview

BIA Ceuticals specializes in developing natural remedies by combining medical cannabis with other medicinal plants. The company's core technology involves proprietary-strain cannabis extracts and natural active ingredients with antiseptic and anti-inflammatory properties. These are formulated into creams and ointments designed to treat common skin disorders such as psoriasis, acne, and hemorrhoids. BIA Ceuticals serves the pharmaceutical and cosmetics markets, aiming to provide effective natural alternatives to standard treatments.

Company Intelligence Q&A

What is BIA Ceuticals' primary focus?

BIA Ceuticals is focused on developing natural remedies that combine medical cannabis with other medicinal plants to treat common symptoms, particularly skin disorders.

What types of products does BIA Ceuticals develop?

BIA Ceuticals develops a series of creams and ointments, including products like Acnecann, Dermacann, Psorcann, and Proctocann, for the treatment of skin conditions such as psoriasis, acne, and hemorrhoids.

What is unique about BIA Ceuticals' product formulation?

The company's products combine extracts from proprietary-strain cannabis with two other natural active ingredients known for their antiseptic and anti-inflammatory properties. They also incorporate a novel patented delivery system to enhance absorption and local bioavailability.

What are the results of BIA Ceuticals' initial preclinical tests?

Initial tests on active compounds in an inflammation model using human skin cells showed a 65-85% reduction of pro-inflammatory markers, a 45% improvement in skin cell survival, and enhanced results when ingredients were combined.

Is BIA Ceuticals licensed?

Yes, BIA Ceuticals is licensed by the Israel Ministry of Health.